A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 9, 2007, Pages 1100-1108

  Poon, Ronnie T P ^a   Tso, Wai Kuen ^a   Pang, Roberta W C ^a   Ng, Kelvin K C ^a   Woo, Regina ^a   Tai, Kin Shing ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DOXORUBICIN; IODINATED POPPYSEED OIL; MICROSPHERE;

AGED; ANGIOGRAPHY; ARTICLE; BLOOD; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; FEMALE; FOLLOW UP; HEPATIC ARTERY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGRAPHY; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEPATIC ARTERY; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 35748960546     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.04.021     Document Type: Article

References (50)

1. Lee HS, Kim KM, Yoon JH, et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002;20:4459-4465.
2. O'Suilleabhain CB, Poon RT, Yong JL, et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003;90:325-331.
3. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004;127(Suppl 1):S124-S218.
4. Venook AP. Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 1999;11:38-41.
5. Tellez C, Benson AB 3rd, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998;82:1250-1259.
6. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-1403.
7. Giroux MF, Baum RA, Soulen MC. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol. 2004;15:289-291.
8. Lorenz K, Brauckhoff M, Behrmann C, et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 2005;138:986-993.
9. Sasaki Y, Imaoka S, Hasegawa Y, et al. Distribution of arterial blood flow in human hepatic cancer during chemotherapy- examination by short-lived 81mKr. Surgery 1985;97:409-414.
10. Taniguchi H, Daidoh T, Shioaki Y, et al. Blood supply and drug delivery to primary and secondary human liver cancers studied with in vivo bromodeoxyuridine labeling. Cancer 1993;71:50-55.
11. Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer 1996;73:877-881.
12. Bhattacharya S, Novell JR, Winslet MC, et al. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 1994;81: 1563-1571.
13. Kameyama M, Imaoka S, Fukuda I, et al. Delayed washout of intratumor blood flow is associated with good response to intraarterial chemoembolization for liver metastasis of colorectal cancer. Surgery 1993;114:97-101.
14. Geschwind JF, Ramsey DE, van der Wal BC, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003;26: 111-117.
15. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
16. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
17. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442.
18. Poyanli A, Rozanes I, Acunas B, et al. Palliative treatment of hepatocellular carcinoma by chemoembolization. Acta Radiol 2001;42:602-607.
19. Lee JK, Chung YH, Song BC, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol 2002;17:52-58.
20. Johnson PJ, Kalayci C, Dobbs N, et al. Pharmacokinetics and toxicity of intraarterial Adriamycin for hepatocellular carcinoma: effect of co-administration of Lipiodol. J Hepatol 1991;13:120- 127.
21. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC beads: in-vitro characterization of a drug delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006;17:335-342.
22. Hong K, Khwaja A, Liapi E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12:2563- 2567.
23. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-235.
24. Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol 1997; 52:36-40.
25. Bruix J, Sherman M, Llovet JM, et al, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
26. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973;32:302-314.
27. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-253.
28. Rand T, Loewe C, Schoder M, et al. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc Intervent Radiol 2005;28:313-318.
29. Ngan H, Lai CL, Fan ST, et al. Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up. J Vasc Interv Radiol 1996;7:419-425.
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
31. Muller HJ, Port RE, Grubert M, et al. The influence of liver metastases on the pharmacokinetics of doxorubicin-a populationbased pharmacokinetics project of the CESAR-APOH. Int J Clin Pharmacol Ther 2003;41:598-599.
32. Dobbs NA, Twelves CJ, Rizzi P, et al. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemother Pharmacol 1994;34:405-410.
33. Hong RL, Tseng YL. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors. The relation between pharmacokinetic property and toxicity. Cancer 2001;91:1826-1833.
34. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 1987;71:1079-1785.
35. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-524.
36. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928.
37. Raoul JL, Herebach D, Bretagne JF, et al. Chemoembolisation of hepatocellular carcinomas: a study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992;70:585-590.
38. Kanematsu T, Furuta T, Takenaka K, et al. A 5-year experience of Lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989;10:98-102.
39. Leung WT, Shiu WCT, Leung N, et al. Treatment of inoperable hepatocellular carcinoma by intra-arterial Lipiodol and 4-epidoxorubicin. Cancer Chemother Pharmacol 1992;29:401-404.
40. Novell JR, Dusheiko G, Markham NI, et al. Selective regional chemotherapy of unresectable hepatic tumors using Lipiodol. HBP Surg 1991;14:223-236.
41. Stefanini GF, Amorati P, Biselli M, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995;75:2427-2434.
42. Furuse J, Ishii H, Satake M, et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol 2003; 26:159-164.
43. Kirchhoff TD, Rudolph KL, Layer G, et al. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol 2006;32:201-207.
44. Liu CL, Ngan H, Lo CM, et al. Ruptured hepatocellular carcinoma as a complication of transarterial oily chemoembolization. Br J Surg 1998;85:512-514.
45. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131Ilabeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-1161.
46. Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992;163:387-394.
47. Groupe D'Etude Et De Traitment Du Carcinome Hepatocellulaire. A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-1261.
48. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129-134.
49. Poon RT, Ngan H, Lo CM, et al. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000;73:109-114.
50. Hwang JI, Chow WK, Hung SW, et al. Development of a safety index of transarterial chemoembolization for hepatocellular carcinoma to prevent acute liver damage. Anticancer Res 2005;25: 2551-2554.